Similarly, CML treatment increased ATF4 and CHOP protein levels by 3.2-fold and 2.9-fold, respectively (p < 0.001 vs. control; Figure 4B). Here, ATF4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.